What's New


First License Agreement in the Therapeutics Field

A nonexclusive license agreement has been concluded with Cellectis Co. in France (Cellectis, listed on the Alternext; ALCLS) as of October 13, 2010, on the basic patent related to the iPS cell technology for which we have been granted a sublicensing right by Kyoto University. This is the first license agreement in the world we have concluded in the field of therapeutics on our basic patent concerning the iPS cell technology.

This is the third license agreement concluded with a foreign company in the field of drug-development research.

Back to top